NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky announces it has commenced an investigation of Aratana Therapeutics, Inc. (NASDAQ:PETX) concerning possible violations of federal securities laws.
On February 6, 2017, Aratana revealed that the Center for Veterinary Medicine ("CVM") had requested more information about ENTYCE, its appetite stimulation drug. Aratana informed shareholders that it “now anticipates that ENTYCE . . . will be commercially available by late 2017” and that the CVM's request was “in connection with the Company's post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale.” Following this news, Aratana stock has fallen as much as $1.57 per share, or 19.55%, to a low of $6.46 during intraday trading on February 6, 2017. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171